Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 3, 2017, Pages 667-676

  Chan, Anthony W H ^a,b   Wong, Grace L H ^a   Chan, Hoi Yun ^a   Tong, Joanna H M ^a,b   Yu, Yau Hei ^a,b   Choi, Paul C L ^a   Chan, Henry L Y ^a   To, Ka Fai ^a,b   Wong, Vincent W S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

APOC3; liver biopsy; PNPLA3; steatosis

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN C3; APOLIPOPROTEIN C;

ADIPOQ GENE; ADULT; APOC3 GENE; ARTICLE; CHRONIC HEPATITIS B; DIABETES MELLITUS; FATTY LIVER; FEMALE; GCKR GENE; GENETIC ASSOCIATION STUDY; HUMAN; HUMAN TISSUE; LEPR GENE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PNPLA3 GENE; PPARG GENE; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; CARCINOMA, HEPATOCELLULAR; COHORT ANALYSIS; COMPLICATION; DIABETIC COMPLICATION; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; LIVER NEOPLASMS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; RISK;

ADULT; APOLIPOPROTEINS C; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DIABETES COMPLICATIONS; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; POLYMORPHISM, GENETIC; PREVALENCE; RETROSPECTIVE STUDIES; RISK; RISK FACTORS;

EID: 85015818476     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13536     Document Type: Article

References (42)

1. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon, France.
2. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015; 386: 1546–1555.
3. European Association for the Study of the Liver, European Organisation For Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56: 908–943.
4. Yuen MF, Hou JL, Chutaputti A. Asia Pacific working party on prevention of hepatocellular C. Hepatocellular carcinoma in the Asia Pacific region. J. Gastroenterol. Hepatol. 2009; 24: 346–353.
5. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 2014; 384: 2053–2063.
6. Loomba R, Yang HI, Su J et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am. J. Epidemiol. 2013; 177: 333–342.
7. Farrell GC, Wong VW, Chitturi S. NAFLD in Asia—as common and important as in the West. Nat. Rev. Gastroenterol. Hepatol. 2013; 10: 307–318.
8. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972–1978.
9. Jan CF, Chen CJ, Chiu YH et al. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10). Int. J. Obes. (Lond) 2006; 30: 794–799.
10. Luo B, Wang Y, Wang K. Association of metabolic syndrome and hepatitis B infection in a Chinese population. Clin. Chim. Acta 2007; 380: 238–240.
11. Wong VW, Wong GL, Chu WC et al. Hepatitis B virus infection and fatty liver in the general population. J. Hepatol. 2012; 56: 533–540.
12. Chen CL, Yang HI, Yang WS et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111–121.
13. Wong GL, Wong VW, Choi PC et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009; 58: 111–117.
14. Hsiang JC, Wong GL, Chan HL, Chan AW, Chim AM, Wong VW. Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B. Aliment. Pharmacol. Ther. 2014; 40: 716–726.
15. Wong GL, Chan HL, Yu Z et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B—a prospective cohort study with paired transient elastography examinations. Aliment. Pharmacol. Ther. 2014; 39: 883–893.
16. Anstee QM, Day CP. The genetics of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013; 10: 645–655.
17. Farrell GC, Chitturi S, Lau GK, Sollano JD, Asia-Pacific Working Party on N. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J. Gastroenterol. Hepatol. 2007; 22: 775–777.
18. W. H. O. Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157–163.
19. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–2752.
20. Bruix J, Sherman M. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–1022.
21. Marcellin P, Gane E, Buti M et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468–475.
22. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N. Engl. J. Med. 2001; 344: 495–500.
23. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 1995; 22: 696–699.
24. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, Network NCR. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810–820.
25. Chuang LY, Yang CH, Tsui KH et al. Restriction enzyme mining for SNPs in genomes. Anticancer Res 2008; 28: 2001–2007.
26. Devlin B, Roeder K, Wasserman L. Analysis of multilocus models of association. Genet. Epidemiol. 2003; 25: 36–47.
27. Wong VW, Chan SL, Mo F et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J. Clin. Oncol. 2010; 28: 1660–1665.
28. Hsiang JC, Gane EJ, Bai WW, Gerred SJ. Type 2 diabetes: a risk factor for liver mortality and complications in hepatitis B cirrhosis patients. J. Gastroenterol. Hepatol. 2015; 30: 591–599.
29. Brouwer WP, van der Meer AJ, Boonstra A et al. The impact of PNPLA3 (rs738409 C > G) polymorphisms on liver histology and long-term clinical outcome in chronic hepatitis B patients. Liver Int. 2015; 35: 438–447.
30. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J. Gastroenterol. Hepatol. 2011; 26: 1361–1367.
31. Wang MM, Wang GS, Shen F, Chen GY, Pan Q, Fan JG. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig. Dis. Sci. 2014; 59: 2571–2579.
32. van Dijk KW, Rensen PC, Voshol PJ, Havekes LM. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? Curr. Opin. Lipidol. 2004; 15: 239–246.
33. Petersen KF, Dufour S, Hariri A et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 2010; 362: 1082–1089.
34. Zhang H, Chen L, Xin Y, Lou Y, Liu Y, Xuan S. Apolipoprotein c3 gene polymorphisms are not a risk factor for developing non-alcoholic fatty liver disease: a meta-analysis. Hepat Mon. 2014; 14: e23100.
35. Zhong DN, Ning QY, Wu JZ et al. Comparative proteomic profiles indicating genetic factors may involve in hepatocellular carcinoma familial aggregation. Cancer Sci. 2012; 103: 1833–1838.
36. Shen J, Wong GL, Chan HL et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment. Pharmacol. Ther. 2014; 39: 532–539.
37. Liu YL, Patman GL, Leathart JB et al. Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J. Hepatol. 2014; 61: 75–81.
38. Pan Q, Zhang RN, Wang YQ et al. Linked PNPLA3 polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B. World J. Gastroenterol. 2015; 21: 8605–8614.
39. Falleti E, Fabris C, Cmet S et al. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int. 2011; 31: 1137–1143.
40. Tong J, Guo J, Hu J, Hou S, Zhang Y, Li Q. Correlation between patatin-like phospholipase domain-containing protein 3 gene polymorphisms and liver cirrhosis in a Chinese Han population with chronic hepatitis B. Hepat Mon. 2014; 14: e18943.
41. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63: 261–283.
42. Fung KT, Fung J, Lai CL, Yuen MF. Etiologies of chronic liver diseases in Hong Kong. Eur. J. Gastroenterol. Hepatol. 2007; 19: 659–664.